Friday, Agios Pharmaceuticals, Inc. (AGIO) announced its decision to discontinue the study of tebapivat, a next-generation oral pyruvate kinase activator designed to provide optimized clinical benefits for patients with rare hematologic diseases.
The decision comes as results from its Phase 2b trial that did not meet the company's predefined threshold to support further development in this indication.
While tebapivat demonstrated evidence of biological activity, clinical benefit was not observed in a sufficient proportion of patients or subgroup of patients during the study.
The company expects to share topline data from this Phase 2 trial in the second half of 2026.
In the pre-market hours, AGIO is falling 5.45 percent, to $28.76 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.